Although no correlations between PD-L1 or PD-1 expression levels and daratumumab-mediated killing were observed, we further investigated whether the combination of daratumumab and nivolumab, a fully human PD-1 blocking antibody, enhances MM cell death in short-term ex vivo cytotoxicity assays. This evidence concerns the gene CD274 and Miyoshi myopathy.